CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionMercer Global Advisors Inc /adv
Latest Disclosed Ownership13,562 shares
Latest Disclosed Value $ 645,129
Mercer Global Advisors Inc /adv reports 52.27% decrease in ownership of CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Mercer Global Advisors Inc /adv filed a 13F-HR form disclosing ownership of 13,562 shares of CRISPR Therapeutics AG (US:CRSP) valued at $645,144 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 28,412 shares of CRISPR Therapeutics AG. This represents a change in shares of -52.27% during the quarter. The current value of the position is $703,054 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,562 -14,850 -52.27 645 -56.68 0.0010
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,412 93 0.33 1,490 -18.86 0.0023
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,319 3,437 13.81 1,835 51.65 0.0031
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,882 13,512 118.84 1,210 213.47 0.0025
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,370 1,390 13.93 387 -1.53 0.0009
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 9,980 -1,598 -13.80 393 -25.62 0.0010
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,578 791 7.33 528 -9.45 0.0012
2024-08-12 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10,787 447 4.32 583 0.0016
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10,340 -696 -6.31 1 0.0020
2024-02-15 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,036 51 0.46 1 0.0021
2023-11-15 2023-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 10,985 395 3.73 0 0.0019
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10,985 395 0 0.0019
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10,590 -2,087 -16.46 1 0.0024
2023-05-16 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 12,677 307 2.48 1 0.0026
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 12,370 137 1.12 1 -100.00 0.0025
2022-11-15 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 12,233 -920 -6.99 799 -0.12 0.0047
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,153 -235 -1.76 800 -4.76 0.0049
2022-05-10 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,388 8,499 173.84 840 127.03 0.0049
2022-02-04 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 4,889 714 17.10 370 -20.77 0.0023
2021-11-10 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 4,175 855 25.75 467 -13.04 0.0033
2021-08-10 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 3,320 372 12.62 537 49.58 0.0041
2021-08-10 2021-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 2,948 383 14.93 359 -8.65 0.0033
2021-05-11 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,948 383 359 0.0034
2021-02-12 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,565 2,565 393 0.0049
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.